Research is being conducted on the role of aldo-keto reductase 1b10 (AKR1B10) in various types of cancer, including digestive tumors, hepatocellular carcinoma, pancreatic carcinoma, and breast cancer. Studies are examining the expression and function of AKR1B10 in these cancers, as well as its potential correlation with clinicopathological features and the immune microenvironment. The enzyme's involvement in cancer development and progression is being explored as a potential target for gene-targeted therapy.